Short answer
Arcturus Therapeutics Holdings Inc. (ARCT) filed an 8-K current report with the SEC on July 2, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Up to $40 million in Thermo Fisher clinical manufacturing support for ARCT-032.
Arcturus Therapeutics Holdings Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Up to $40 million in Thermo Fisher clinical manufacturing support for ARCT-032
- Arcturus commits up to $40 million to PPD for CRO services
- Collaboration covers technical transfer, clinical batches, fill-finish, release, and stability testing
- Thermo Fisher gains exclusive commercial manufacturing rights upon regulatory approval
- Five-year initial term with annual renewals; alternative manufacturing limited to supply shortfalls
Item 7.01 · Regulation FD Disclosure
- Reg FD disclosure consists solely of filing-liability and incorporation-by-reference disclaimers
- Investors should not expect substantive operating, clinical, financial, or strategic information from this excerpt
Item EX-99.1 · Exhibit EX-99.1
- Strategic manufacturing collaboration with Thermo Fisher supporting ARCT-032 cystic fibrosis Phase 3 development and potential commercialization
- Thermo Fisher to provide Phase 3 manufacturing, clinical research, and related services through its PPD clinical research business
- Exclusive commercial manufacturing rights contingent on regulatory approval under a separate commercial agreement
- Positive Phase 2 results remain a prerequisite for Phase 3, preserving significant clinical and regulatory risk
- Agreement strengthens manufacturing readiness while potentially adding future supply-chain dependence on Thermo Fisher
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Arcturus Therapeutics Holdings Inc. 8-K filings
Get the next ARCT 8-K as it lands
Follow ARCT for push alerts, or ask the research agent what this filing means.